Augurex Life Sciences Corp., a leader in autoimmune biomarker diagnostics, has announced that ARUP Laboratories, a prominent national reference lab in the U.S., has launched the 14-3-3η test as part of its diagnostic offerings. This agreement is set to significantly improve the early detection and management of rheumatoid arthritis (RA), equipping clinicians with a valuable tool to enhance patient care and outcomes.
The 14-3-3η protein is a crucial biomarker for the early detection and management of rheumatoid arthritis (RA). Elevated levels of 14-3-3η indicate more severe disease and a higher risk of joint damage, making it an essential diagnostic tool for identifying patients who may benefit from early intervention. As this test becomes more accessible, clinicians will be better equipped to identify individuals at greater risk, facilitating more personalized patient care.
“We are thrilled to partner with ARUP Laboratories to integrate the 14-3-3η test into their diagnostic offerings, reinforcing our commitment to advancing the early diagnosis and treatment of rheumatoid arthritis,” said Neil Klompas, CEO of Augurex. “This collaboration is a significant milestone in our mission to expand access to the 14-3-3η test for clinicians and patients across the U.S., aligning with our shared goal of improving health outcomes for those affected by rheumatoid arthritis.”
ARUP offers over 3,000 tests, including routine screenings and specialized molecular and genetic assays. The lab serves clients nationwide, including top university teaching hospitals, children’s hospitals, multihospital groups, major commercial labs, and various government facilities.
About Augurex
Augurex is a commercial-stage diagnostics company focused on the early identification and diagnosis of autoimmune disorders, enabling optimized and personalized treatment options for patients globally. Its lead diagnostic test, known as 14-3-3η in the U.S. and JOINTstat® in Canada and Europe, plays a vital role in diagnosing and managing inflammatory diseases such as rheumatoid arthritis, lupus, and other autoimmune conditions. Additionally, SPINEstat® extends Augurex’s biomarker-driven diagnostic portfolio into axial spondyloarthritis (axSpA), an autoimmune disease often misdiagnosed as low back pain, which, if untreated, can lead to impaired spinal mobility and vertebral fusion.
